Company Metrics

• 0 P/E
• 28.24 P/S
• 5.1 P/B
• -0.639 EPS
• -833.06% Cash ROIC
• 9.87 Cash Ratio
• 0 / 0% Dividend
• 554,571.00 Avg. Vol.
• 37.80M Shares
• 173.6M Market Cap.

Company Description

Nanosphere, Inc. develops, manufactures, and markets a molecular diagnostics platform, the Verigene System that enables genomic and protein testing on a single platform. Its proprietary nanoparticle technology provides the ability to run multiple tests simultaneously on the same sample, as well as simplifies molecular diagnostic testing. The company develops diagnostic tests for markers, which reveal the existence of various medical conditions, including cardiovascular, respiratory, cancer, autoimmune, neurodegenerative, and other infectious diseases, as well as for pharmacogenomics. It also engages in developing and commercializing genomic and protein assays, including hyper-coagulation, warfarin metabolism, cystic fibrosis, respiratory virus panel, hemochromatosis, blood infection panel, cardiac troponin I, connective tissue, prostate specific antigen, and biomarker validation. Nanosphere intends to market its solutions for applications in the hospital-based laboratories and academic research institutions in the United States. The company is headquartered in Northbrook, Illinois.
less

Nanosphere, Inc. develops, manufactures, and markets a molecular diagnostics platform, the Verigene System that enables genomic and protein testing on a single platform. Its proprietary nanoparticle technology provides the ability to run multiple tests simultaneously on the same sample, as well as simplifies molecular diagnostic testing. The company develops diagnostic tests for markers, which rev...
more

News